NETRI has announced the commercial launch of its NeuroFluidics™ MEA line, developed in collaboration with Axion BioSystems and compatible with the company’s flagship Maestro MultiElectrode Array (MEA) systems. The new product line offers a range of ready-to-use compartmentalized microfluidic devices with an integrated MEA layer, providing high-throughput organs-on-chip platforms for disease research and drug discovery in neurology, dermatology, and other fields.
NETRI has announced the commercial launch of its NeuroFluidics™ MEA line, developed in collaboration with Axion BioSystems and compatible with the company’s flagship Maestro MultiElectrode Array (MEA) systems. The new product line offers a range of ready-to-use compartmentalized microfluidic devices with an integrated MEA layer, providing high-throughput organs-on-chip platforms for disease research and drug discovery in neurology, dermatology, and other fields.